Sol-Gel Technologies (NASDAQ:SLGL) has seen its target price significantly increased by HC Wainwright, which raised the figure from $6 to $50 in a research note released on Monday, according to reports from MarketBeat Ratings. The firm has issued a buy rating for the stock, reflecting a positive outlook.
In addition to the price target adjustment, HC Wainwright has provided earnings estimates for Sol-Gel Technologies for various future quarters. The anticipated earnings per share (EPS) for Q3 2025 is expected to be ($2.09), while Q4 2025 earnings are projected at $0.40 EPS. For the full fiscal year 2025, the earnings estimate stands at ($0.68) EPS. Looking further ahead, the firm forecasts Q1 2026 earnings at ($1.63) EPS, Q2 2026 at ($1.74) EPS, Q3 2026 at ($1.78) EPS, Q4 2026 at ($1.47) EPS, and a total for FY2026 of ($6.60) EPS.
Additional analysis from other brokerages has also been noted. On October 8, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sol-Gel Technologies. Earlier, on September 13, Wall Street Zen upgraded the stock to a “buy” rating. Currently, one analyst has assigned a Buy rating, while another has opted for a Hold rating. MarketBeat.com indicates that the stock carries a consensus rating of “Moderate Buy,” with an average target price set at $50.
In terms of trading performance, Sol-Gel Technologies experienced a slight increase of 0.4% recently. The company last reported its quarterly earnings on August 15, where it posted an EPS of $4.17 for the quarter, surpassing the consensus estimate of ($0.67) by a notable margin of $4.84. Despite this, the company recorded a negative return on equity of 11.80% and a negative net margin of 14.25%. The revenue for the quarter was reported at $17.26 million, significantly exceeding analyst expectations of $2.86 million.
Looking forward, analysts predict that Sol-Gel Technologies will achieve an EPS of -0.28 for the current fiscal year. The company, along with its subsidiary Sol-Gel Technologies Inc, focuses on developing topical dermatological treatments for severe skin conditions in Israel. Its product offerings include Twyneo, a daily topical cream designed for acne vulgaris, and Epsolay, a cream aimed at treating papulopustular rosacea.
